Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Selexipag (ACT-293987)(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 10,000 | |||
10 mg | 在庫あり | ¥ 13,500 | |||
25 mg | 在庫あり | ¥ 19,500 | |||
50 mg | 在庫あり | ¥ 22,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,500 |
説明 | Selexipag (ACT-293987)(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH). |
In vitro | NS-304 is an orally available and long-acting IP receptor agonist prodrug, and its active form, MRE-269, is highly selective for the IP receptor. NS-304 inhibits the binding of [3H]Iloprost to the human and rat IP receptors in a concentration-dependent manner. The Ki is 260 nM for the human IP receptor and 2100 nM for the rat IP receptor. The intracellular cAMP levels in hIP-CHO cells are increased in a concentration-dependent manner by treatment with NS-304 with EC50 of 177 nM. NS-304 also inhibits platelet aggregation in humans and monkeys with IC50 values of 5.5 and 3.4 μM, respectively, but it shows no inhibition in dogs (IC50 of >100 μM)[1]. |
In vivo | Following oral administration, MRE-269 achieves a peak concentration (Cmax) of 1.1 μg/mL in rats and 9.0 μg/mL in dogs. When administered intraduodenally at doses of 1 or 3 mg/kg, NS-304 enhances femoral skeletal blood flow (FSBF) in anesthetized rats for over 4 hours in a dose-dependent manner. Notably, a dose of 3 mg/kg NS-304 significantly elevates FSBF, achieving a peak increase of 93% one hour post-administration[1]. |
細胞研究 | NS-304 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. CHO cells expressing the human IP receptor (hIP-CHO cells) are seeded at 1×105 cells/well in a 24-well plate and cultured for 48 h. The cells are washed with Dulbecco's phosphate-buffered saline without divalent cations, preincubated in the medium for 1 h at 37°C, and then incubated for 15 min at 37°C with medium containing each drug in the presence of 500 μM 3-isobutyl-1-methylxanthine. The medium is removed, and perchloric acid solution is added to terminate the reaction. Intracellular cAMP levels are measured by enzymelinked immunosorbent assay[1]. |
別名 | NS-304, ACT-293987, Uptravi |
分子量 | 496.62 |
分子式 | C26H32N4O4S |
CAS No. | 475086-01-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (30.2 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Selexipag 475086-01-2 GPCR/G Protein Immunology/Inflammation Others Prostaglandin Receptor NS 304 NS-304 ACT 293987 ACT-293987 Uptravi Inhibitor inhibit NS304 ACT293987 inhibitor